Herantis Pharma Board of Directors’ proposal for dividend

Herantis Pharma Plc
Company release 27 Feb 2015 at 5:30 pm
Herantis Pharma Plc.
Company release 27 February 2015 at 5:30 pm

The  parent  company  of  Herantis  Pharma  group  is  Herantis Pharma Plc whose
distributable  equity was €25.7  million according to  balance sheet 31 December
2014. Herantis  Pharma Plc had  no revenue in  2014. The financial result of the
parent company for 2014 was €-3.5 million.

Herantis  was  listed  on  the  First  North  Finland  marketplace of NASDAQ OMX
Helsinki  stock exchange. An  Initial Public Offering  produced a total of €14.3
million before share issue expenses. The proceeds of the IPO will mainly be used
for  clinical development of  the three main  drug candidates of Herantis Pharma
group.

The  Board of Directors proposes  to the Annual General  Meeting convening on 9
April 2015 that no dividend for the financial year 2014 will be paid.

Herantis Pharma Plc

Board of Directors

Further information:

Herantis Pharma plc., Pekka Simula, CEO, telephone: +358 40 7300 445
Company web site: www.herantis.com
Certified Advisor: UB Capital Oy, telephone: +358 9 2538 0225

About Herantis Pharma Plc

Herantis  Pharma  Plc.  is  a  pharmaceutical  company  specialised  in new drug
research and development. The company focuses on diseases with an unmet clinical
need.  These diseases include for example dry eye syndrome, Parkinson's disease,
and  secondary lymphedema. We believe  our drugs are the  first or best in their
class  and have  the potential  to change  treatment strategies of diseases. The
shares of Herantis Pharma Plc. are listed on the First North Finland marketplace
run by NASDAQ Helsinki stock exchange.